Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03725618 · ClinicalTrials.gov registry record · Phase 4
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
A Phase 4 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,788
- Enrollment target
NCT03725618 is a Phase 4 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 1,788 participants.
The verdict
NCT03725618, a Phase 4 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,788 participants
- Enrollment target
Study Summary
A randomized clinical trial comparing fractional dose Yellow Fever vaccination to the full dose among children aged 9-23 months in Uganda. Children will have immune response assessed at baseline, 4 weeks, and 12 months after vaccination. Enrolled participants will be randomized to one of three arms: A. One-fifth fractional dose (0.1 ml) administered subcutaneously B. One-half fractional dose (0.25 ml) administered subcutaneously C. Full dose (0.5 ml) administered subcutaneously
Interventions
- BIOLOGICAL Yellow Fever 17DD Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,788 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2021-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03725618
The ClinicalTrials.gov registry entry for NCT03725618 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,788 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Yellow Fever 17DD Vaccine is the first listed.
NCT03725618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03725618 about?
NCT03725618 is a clinical study titled "Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old". A randomized clinical trial comparing fractional dose Yellow Fever vaccination to the full dose among children aged 9-23 months in Uganda. Children will have immune response assessed at baseline, 4 weeks, and 12 months after vaccination. Enrolled participants will be randomized to one of three arms...
What is the current status of trial NCT03725618?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,788 participants. The study started on 2018-11-01. Estimated completion is 2021-09-01.
What interventions are being tested in trial NCT03725618?
The interventions under investigation include: Yellow Fever 17DD Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03725618?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.